Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell
Sheila A
SA
Division of Health Practice, Auckland University of Technology - Akoranga Campus, Northcote, Auckland, New Zealand. s.doggrell@xtra.co.nz
D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use; D002186:Cannabinoids / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000639:trends; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000077285:Rimonabant
D019440:Anti-Obesity Agents; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant